These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 8231259)

  • 21. Occurrence of a T cell lymphoma in a patient with chronic myeloid leukemia treated with alpha interferon.
    Mahé B; Gaillard F; Labadie F; Papin S; Letortorec S; Moreau P; Harousseau JL; Milpied N
    Leuk Lymphoma; 1995 Nov; 19(5-6):515-7. PubMed ID: 8590856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha.
    Reuben JM; Lee BN; Johnson H; Fritsche H; Kantarjian HM; Talpaz M
    Clin Cancer Res; 2000 May; 6(5):1671-7. PubMed ID: 10815885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytogenetic response to alpha-interferon is predicted in early chronic phase chronic myeloid leukemia by M-bcr breakpoint location.
    Elliott SL; Taylor KM; Taylor DL; Rodwell RL; Williams BF; Shuttlewood MM; Wright SJ; Eliadis PE; Bunce IH; Frost TJ
    Leukemia; 1995 Jun; 9(6):946-50. PubMed ID: 7596182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prolonged hematological remission by mitoxantrone and interferon--alpha-2b in a child with resistant Philadelphia chromosome-positive chronic myelogenous leukemia.
    Duru F; Tuncer M; Hiçsönmez G
    Eur J Haematol; 1993 Sep; 51(3):173-4. PubMed ID: 8405332
    [No Abstract]   [Full Text] [Related]  

  • 26. [Interferon therapy for chronic myelogenous leukemia].
    Shibata A; Hashimoto S
    Gan To Kagaku Ryoho; 1993 Feb; 20(2):200-6. PubMed ID: 8434957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of interferon in the treatment of chronic myelogenous leukemia in chronic phase.
    Guilhot F
    Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S39-46. PubMed ID: 8177714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
    O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
    Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The treatment of chronic myeloleukemia with recombinant alfa-2 interferon].
    Strozha I; Petukhov V; Bondare D; Feldmane G; Duks A; Teilane I; Medne I; Mauritsas M; Grinberga L
    Ter Arkh; 1993; 65(10):62-6. PubMed ID: 8296238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon.
    Breccia M; Diverio D; Pane F; Nanni M; Russo E; Biondo F; Frustaci A; Gentilini F; Alimena G
    Leuk Res; 2006 Dec; 30(12):1577-9. PubMed ID: 16630657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Collection of Philadelphia-negative stem cells using recombinant human granulocyte colony-stimulating factor in chronic myeloid leukemia patients treated with alpha-interferon.
    Hernández-Boluda JC; Carreras E; Cervantes F; Marín P; Arellano-Rodrigo E; Rovira M; Solé F; Lloveras E; Espinet B; Ocejo A; Montserrat E
    Haematologica; 2002 Jan; 87(1):17-22. PubMed ID: 11801461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment with interferon alfa-2a in the chronic phase of Philadelphia-positive chronic myeloid leukemia].
    Steegmann JL; Lavilla E; Somolinos N; Pérez-Sánchez M; Lamana M; Olmeda F; Cámara R; Arranz R; Ferro MT; Fernández-Rañada JM
    Sangre (Barc); 1992 Oct; 37(5):375-81. PubMed ID: 1293778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia.
    Talpaz M; Kurzrock R; Kantarjian H; Rothberg J; Saks S; Evans L; Gutterman JU
    Cancer; 1991 Nov; 68(10):2125-30. PubMed ID: 1913450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinicopathologic, cytogenetic, and molecular studies of 13 Chinese Patients with Ki-1 anaplastic large cell lymphoma. Special emphasis on the tumor response to 13-cis retinoic acid.
    Chou WC; Su IJ; Tien HF; Liang DC; Wang CH; Chang YC; Cheng AL
    Cancer; 1996 Oct; 78(8):1805-12. PubMed ID: 8859196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined therapy interferon and chemotherapy in chronic myelogenous leukemia.
    Guilhot F; Dreyfus B; Desmarest MC; Giraud C; Huret JL; Brizard A; Tanzer J
    Nouv Rev Fr Hematol (1978); 1989; 31(2):171-3. PubMed ID: 2771633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment with natural human interferon alpha of a CML-patient with antibodies to recombinant interferon alpha-2b.
    Freund M; von Wussow P; Knüver-Hopf J; Mohr H; Pohl U; Exeriede G; Link H; Wilke HJ; Poliwoda H
    Blut; 1988 Nov; 57(5):311-5. PubMed ID: 3196882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia.
    Sacchi S; Kantarjian H; O'Brien S; Cohen PR; Pierce S; Talpaz M
    J Clin Oncol; 1995 Sep; 13(9):2401-7. PubMed ID: 7666100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The use of interferon-alfa (reaferon) in patients with chronic myeloleukemia].
    Machiulaĭtene ER; Lasunskaia EB; Nefedova IuB; Perekalina TA; Salogub GN; Poliakova LE
    Ter Arkh; 1996; 68(10):44-7. PubMed ID: 9026942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.